Glycated albumin: sample stability of an emerging glycaemic control biomarker  by Reynolds, A.N. et al.
Abstracts / Journal of Nutrition & Intermediary Metabolism 1 (2014) 1e5522¼ 0.0066, p ¼ 0.034, 25 nmol/L for FRT, blow ¼ 0.684 (0.075, 1.292); Db ¼
0.697, p¼ 0.027 and LMS, blow¼ 1.703 (0.241, 3.165); Db¼ 1.802, p¼ 0.020,
and 60 nmol/L for ST, blow ¼ 0.030 (-0.001, 0.061); Db ¼ 0.051, p ¼ 0.038.
Conclusions: In middle-aged women, the point at which relationships be-
tween 25(OH)D and musculoskeletal outcomes change varies for different
outcomes. The current cut-off of 50 nmol/L appears too high for some out-
comesbut reasonableoverall to optimiseboneandbalance in thispopulation.
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Background/Aims: Glycated albumin (GA) is an emerging biomarker of
glycaemic control reﬂecting glycaemia in the previous two weeks. It is the
ratio of glycated to total albumin expressed as a percentage. It is stable to
day-to-day ﬂuctuations in glycaemia; independent of plasma volume or
albumin concentration; and unaffected by haemodialysis or haemglobi-
nopathies. Used clinically in India and China, GA correlates with HbA1c
and fasting glucose. Validation of sample stability is required.
Methods: Three experiments were undertaken using plasma samples of
people with type 2 diabetes. 1. Short-term stability of 15 samples under-
going freeze-thaw cycles. 2. Short-term stability of 15 samples stored at 4
oC for up to two days. 3. Long-term stability of 25 samples assayed 5 years
ago and subsequently stored at -80 oC.
Results: The mean GA of fresh samples and those undergoing 1, 2, 5 and 10
freeze-thaw cycles were 18.15, 18.14, 18.08, 18.14, and 18.19%, respectively
e values did not differ from baseline (p ¼ 0.86). The mean GA of thawed
samples stored at 4 oC for 12, 24 and 48 h were 17.36, 17.33, 17.37 and 17.61,
respectively e the 48 h sample differed from baseline (p ¼ 0.009). The
mean GAof samples stored at -80 oC for 5 years (34.99%) was double that of
the fresh samples (18.89%).
Conclusions: GA appears stable to multiple short-term freeze thaw cycles
and to storage at 4 oC for up to 24 h. Long-term storage resulted in an
appreciable increase in GA. Further work is required to characterise the
stability of GA under various storage conditions.
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Background/Aims: An increasing prevalence of heat waves presents the
challenge of managing hyperthermia, particularly in intensively farmed
animals. Therefore the aim of this experiment was to quantify protective
effects of anti-oxidants selenium (Se) or vitamin E (VE) during hyper-
thermia in growing pigs.
Methods: Thirty-six gilts (Large White  Landrace, 28 ± 4 kg) were fed
control (0.24 ppm Se, 17 IU/kg VE), Se (1.0 ppm Se yeast, 17 IU/kg VE), or VE
(0.24 ppm Se, 200 IU/kg VE) 80% restricted for 14 days, then exposed to
thermoneutral (TN) vs. cyclic hyperthermia (HT) for seven days (20 C vs.
35 C 0900-1700h/28 C). Hyperthermia was assessed by skin and rectal
temperature (ST and RT), respiration rate (RR), heart rate (HR) and blood
bicarbonate. Data were analysed using restricted maximum likelihood for
the effects and interactions of diet, temperature, time.
Results: As expected with restricted feeding, feed intake was not affected,
so effects could be ascribed to HTor antioxidants rather than to differences
in feed intake. Despite similar feed intakes, HT increased body weight (p <
0.001). HT increased ST and RT (p < 0.001), and both were mitigated by Se
(p ¼ 0.019 and < 0.001). RR increased during HT (p < 0.001) which was
ameliorated by Se, but elevated with VE (p ¼ 0.006). HT reduced HR at1600h, which was mitigated by Se and VE (p < 0.001). Also, VE protected
reductions in blood bicarbonate during HT (p ¼ 0.016).
Conclusions: Short term Se or VE supplementation ameliorated the effects
of hyperthermia in growing pigs.
Funding source(s): Australian Pork Limited, Department of Agriculture,
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Background/Aims: Recent single centre papers suggest that calcium
supplementation increases the risk of coronary heart disease. These risks
were re-evaluated by a consortium who undertook a meta-analysis of all
randomised controlled trials of calcium supplements with or without
vitamin D for coronary heart disease events and all-cause mortality.
Methods: The Cochrane Central Register of Controlled Trials, MEDLINE, and
EMBASE databases were searched from January 1966 to May 2013 for
randomised controlled trials of calcium supplementation with or without
vitaminD inwomen aged over 50 yearswith event data fromhospitalisation
veriﬁed by clinical review or hospital record and/or death certiﬁcate data.
Results: Of 661 potentially eligible studies, 18 met the inclusion criteria,
reporting data from 63,564 participants with 3,390 coronary heart disease
events and 4,157 deaths. Coronary heart disease hospitalisation or death
events pooled RR for calcium of 1.02 (95% CI: 0.96, 1.09; p¼ 0.51). All-cause
mortality data (17 trials) had an RR for calcium of 0.96 (95%CI: 0.91, 1.02; p
¼ 0.18). Heterogeneity among the trials was low for both primary out-
comes (I2¼ 0%). Secondary outcomes RR for myocardial infarction, chronic
coronary heart disease and angina pectoris and acute coronary syndrome
were 1.08 (95%CI: 0.92,1.26; p¼ 0.33), 0.92 (95%CI: 0.73,1.15; p¼ 0.46) and
1.09 (95%CI: 0.95, 1.24; p ¼ 0.22) respectively.
Conclusions: Calcium supplementation with or without vitamin D does
not increase coronary heart disease or all-cause mortality risk in women
consuming calcium to prevent fractures.
Funding source(s): Raine Medical Research Foundation Priming Grant.
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Background/Aims: Vitamin D has been associated with psychological
wellbeing in previous studies, for example depression, anxiety, and sea-
sonal affective disorder. We tested whether vitamin D supplementation
over winter is beneﬁcial for psychological wellbeing in healthy women.
Methods: One hundred and ﬁfty two healthy women (18-40 years of age)
in Dunedin, New Zealand (S46) have been randomly assigned to receive
six monthly doses of 50,000 IU of oral vitamin D3 or placebo. They
completed the Centre for Epidemiologic Studies Depression Scale (CES-D),
the anxiety subscale of the Hospital Anxiety and Depression Scale (HADS),
and the Flourishing Scale (FS) every month. Additionally, they reported on
positive and negative moods every twomonths for three consecutive days.
Participants provided a blood sample for 25-hydroxyvitamin D analysis at
the beginning and at the end of the study. Differences for each wellbeing
measure between the groups were analysed using ANCOVA, controlling for
confounders and baseline values. Mixed model regression was used to test
the treatment by time interaction effect.
